FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2185001055> ?p ?o ?g. }

• W2185001055 endingPage "260" @default.
• W2185001055 startingPage "248" @default.
• W2185001055 abstract "Despite advances in polymeric nanoparticles (NPs) as effective delivery systems for anticancer drugs, rapid clearance from blood and poor penetration capacity in heterogeneous tumors still remain to be addressed. Here, a dual coating of poly (ethylene glycol)-poly (d,l-lactic acid) (PEG-PDLLA) and water-soluble chitosan oligosaccharide (CO) was used to develop PLGA-based NPs (PCPNPs) with colloidal stability for delivery of paclitaxel (PTX). The PCPNPs were prepared by a modified nanoprecipitation process and exhibited homogeneous size of 165.5 nm, and slight positive charge (+3.54 mV). The single PEG-PDLLA-coated PLGA NPs (PPNPs) with negative charge (−13.42 mV) were prepared as control. Human breast cancer MDA-MB-231 cell and mice MDA-MB-231 xenograft model were used for in vitro and in vivo evaluation. Compared to Taxol®, both PCPNPs and PPNPs increased the intracellular uptake and exerted stronger inhibitory effect on tumor cells in vitro, especially for PCPNPs. Particularly, due to the near neutral surface charge and shielding by the dual coating, the blank cationic NP presented low cytotoxicity. With the synergistic action of PEG-PDLLA and CO, PCPNPs not only strongly inhibited macrophage uptake and extended the blood circulation time, but also improved the selective accumulation and interstitial penetration capacity to/in tumor site. Consequently, a significantly enhanced antitumor efficacy was observed for the cationic PCPNPs. Our findings suggest that, the dual PEG-PDLLA/CO coating can effective improve the tumor accumulation and interstitial penetration of NPs and, therefore may have great potential for tumor treatment. Rapid clearance from blood and poor penetration capacity in heterogeneous tumors represent great challenge for polymeric nanoparticles (NPs) as effective delivery systems for anticancer drugs. This study provides a promising cationic nanoparticle (PCPNPs) with dual coating of chitosan oligosaccharide (CO) and PEG-PDLLA to address the above problem. The PCPNPs prepared with 165.5 nm and slight positive charge (+3.54 mV) showed an improved accumulation and interstitial penetration capacity to/in tumor site, and thus led to an enhanced antitumor efficacy. This is the first time to report the cooperative effect of PEG-PDLLA and CO on PLGA NPs in this field. This work can arouse broad interests among researchers in the fields of nanomedicine, nanotechnology, and drug delivery system." @default.
• W2185001055 created "2016-06-24" @default.
• W2185001055 creator A5008542211 @default.
• W2185001055 creator A5010294985 @default.
• W2185001055 creator A5011540763 @default.
• W2185001055 creator A5035444966 @default.
• W2185001055 creator A5049078993 @default.
• W2185001055 creator A5059317683 @default.
• W2185001055 creator A5060634768 @default.
• W2185001055 creator A5071418683 @default.
• W2185001055 creator A5075411333 @default.
• W2185001055 creator A5082156426 @default.
• W2185001055 date "2016-01-01" @default.
• W2185001055 modified "2023-10-12" @default.
• W2185001055 title "Preferential tumor accumulation and desirable interstitial penetration of poly(lactic-co-glycolic acid) nanoparticles with dual coating of chitosan oligosaccharide and polyethylene glycol-poly(d,l-lactic acid)" @default.
• W2185001055 cites W1968583232 @default.
• W2185001055 cites W1971390550 @default.
• W2185001055 cites W1974892535 @default.
• W2185001055 cites W1975429674 @default.
• W2185001055 cites W1975603353 @default.
• W2185001055 cites W1982106711 @default.
• W2185001055 cites W1984659376 @default.
• W2185001055 cites W1993430869 @default.
• W2185001055 cites W1996315170 @default.
• W2185001055 cites W2001286327 @default.
• W2185001055 cites W2001492234 @default.
• W2185001055 cites W2009805582 @default.
• W2185001055 cites W2020398834 @default.
• W2185001055 cites W2021250900 @default.
• W2185001055 cites W2027876233 @default.
• W2185001055 cites W2029041094 @default.
• W2185001055 cites W2031771095 @default.
• W2185001055 cites W2034534448 @default.
• W2185001055 cites W2034776254 @default.
• W2185001055 cites W2035991148 @default.
• W2185001055 cites W2043978056 @default.
• W2185001055 cites W204512410 @default.
• W2185001055 cites W2054057500 @default.
• W2185001055 cites W2057876241 @default.
• W2185001055 cites W2071447376 @default.
• W2185001055 cites W2071471314 @default.
• W2185001055 cites W2076152464 @default.
• W2185001055 cites W2078057254 @default.
• W2185001055 cites W2082511916 @default.
• W2185001055 cites W2083256312 @default.
• W2185001055 cites W2098054841 @default.
• W2185001055 cites W2101312385 @default.
• W2185001055 cites W2108615682 @default.
• W2185001055 cites W2110270192 @default.
• W2185001055 cites W2116833838 @default.
• W2185001055 cites W2133031869 @default.
• W2185001055 cites W2137486449 @default.
• W2185001055 cites W2141518860 @default.
• W2185001055 cites W2146351833 @default.
• W2185001055 cites W2157770632 @default.
• W2185001055 cites W2166216910 @default.
• W2185001055 cites W2315385973 @default.
• W2185001055 doi "https://doi.org/10.1016/j.actbio.2015.10.017" @default.
• W2185001055 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26476340" @default.
• W2185001055 hasPublicationYear "2016" @default.
• W2185001055 type Work @default.
• W2185001055 sameAs 2185001055 @default.
• W2185001055 citedByCount "60" @default.
• W2185001055 countsByYear W21850010552016 @default.
• W2185001055 countsByYear W21850010552017 @default.
• W2185001055 countsByYear W21850010552018 @default.
• W2185001055 countsByYear W21850010552019 @default.
• W2185001055 countsByYear W21850010552020 @default.
• W2185001055 countsByYear W21850010552021 @default.
• W2185001055 countsByYear W21850010552022 @default.
• W2185001055 countsByYear W21850010552023 @default.
• W2185001055 crossrefType "journal-article" @default.
• W2185001055 hasAuthorship W2185001055A5008542211 @default.
• W2185001055 hasAuthorship W2185001055A5010294985 @default.
• W2185001055 hasAuthorship W2185001055A5011540763 @default.
• W2185001055 hasAuthorship W2185001055A5035444966 @default.
• W2185001055 hasAuthorship W2185001055A5049078993 @default.
• W2185001055 hasAuthorship W2185001055A5059317683 @default.
• W2185001055 hasAuthorship W2185001055A5060634768 @default.
• W2185001055 hasAuthorship W2185001055A5071418683 @default.
• W2185001055 hasAuthorship W2185001055A5075411333 @default.
• W2185001055 hasAuthorship W2185001055A5082156426 @default.
• W2185001055 hasConcept C10138342 @default.
• W2185001055 hasConcept C12554922 @default.
• W2185001055 hasConcept C127413603 @default.
• W2185001055 hasConcept C13965031 @default.
• W2185001055 hasConcept C155672457 @default.
• W2185001055 hasConcept C162324750 @default.
• W2185001055 hasConcept C171250308 @default.
• W2185001055 hasConcept C178790620 @default.
• W2185001055 hasConcept C185592680 @default.
• W2185001055 hasConcept C192562407 @default.
• W2185001055 hasConcept C2775920511 @default.
• W2185001055 hasConcept C2776964284 @default.
• W2185001055 hasConcept C2777516009 @default.
• W2185001055 hasConcept C2779732960 @default.
• W2185001055 hasConcept C2780165375 @default.
• W2185001055 hasConcept C42360764 @default.

• next